Wasatch Advisors Inc. Decreases Holdings in Amgen, Inc. (AMGN)

Wasatch Advisors Inc. lessened its holdings in Amgen, Inc. (NASDAQ:AMGN) by 35.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,540 shares of the medical research company’s stock after selling 12,508 shares during the quarter. Wasatch Advisors Inc.’s holdings in Amgen were worth $3,920,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in AMGN. Foundry Partners LLC boosted its holdings in shares of Amgen by 25.5% during the second quarter. Foundry Partners LLC now owns 90,420 shares of the medical research company’s stock valued at $15,573,000 after acquiring an additional 18,375 shares during the period. First Trust Advisors LP lifted its holdings in Amgen by 23.1% in the second quarter. First Trust Advisors LP now owns 431,407 shares of the medical research company’s stock worth $74,301,000 after purchasing an additional 80,852 shares during the period. Crescent Grove Advisors LLC acquired a new stake in Amgen in the second quarter worth about $302,000. DekaBank Deutsche Girozentrale lifted its holdings in Amgen by 2.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock worth $152,927,000 after purchasing an additional 24,219 shares during the period. Finally, Sterling Global Strategies LLC lifted its holdings in Amgen by 33.8% in the second quarter. Sterling Global Strategies LLC now owns 1,978 shares of the medical research company’s stock worth $341,000 after purchasing an additional 500 shares during the period. 78.03% of the stock is owned by institutional investors.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Tuesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The stock has a market capitalization of $132,259.19, a PE ratio of 71.42, a price-to-earnings-growth ratio of 2.19 and a beta of 1.42. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. Amgen’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.89 EPS. equities analysts expect that Amgen, Inc. will post 13.21 earnings per share for the current year.

Amgen declared that its board has authorized a stock buyback plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.88%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is 205.45%.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 4,575 shares of company stock worth $818,361. Company insiders own 0.19% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Atlantic Securities downgraded shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective for the company. in a report on Monday, February 5th. Royal Bank of Canada reduced their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a report on Thursday, October 26th. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $191.84.

ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/wasatch-advisors-inc-decreases-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply